FIELD: medicine.
SUBSTANCE: invention concerns medicine, particularly gastoenterology, and concerns treating ulcerative colitis and Crohn's disease. That is ensured by the oral introduction of the probiotic Bifiform in dose 2-3 capcules. It is followed by the 4-5-fold introduction of mesenchymal stem cells in number 150-200 mil. cells in 0.5 to 1.5 ml into a mucous membrane of changed intestinal segments. Further, Bifiform is introduced in dose 1 capsule 3 times a day for 3 weeks.
EFFECT: method provides higher clinical effectiveness in said diseases.
3 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2463055C2 |
METHOD OF EVALUATING EFFICIENCY OF CROHN'S DISEASE AND ULCERATIVE COLITIS TREATMENT | 2008 |
|
RU2391914C2 |
METHOD OF ASSESSING CLINICAL EFFECTIVENESS IN INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2477478C1 |
METHOD OF EARLY DIAGNOSTICS OF DIVERTICULAR DISEASE | 2009 |
|
RU2391667C1 |
METHOD OF TREATING SECONDARY LACTASE DEFICIENCY | 2011 |
|
RU2477633C2 |
METHOD FOR EVALUATING CLINICAL EFFECTIVENESS OF MESENCHYMAL STROMAL CELLS FOR INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2463596C1 |
METHOD OF TREATING CYTOMEGALOVIRUS INFECTION | 2013 |
|
RU2540474C2 |
DIAGNOSTIC TECHNIQUE FOR BRONCHIAL OBSTRUCTION ACCOMPANYING INFLAMMATORY INTESTINAL DISEASES | 2011 |
|
RU2451488C1 |
METHOD OF TREATING ULCERATIVE PROCTOSIGMOIDITIS | 2008 |
|
RU2367450C1 |
THERAPY OF INFLAMMATORY BOWEL DISEASES | 2008 |
|
RU2364405C1 |
Authors
Dates
2012-09-10—Published
2011-01-12—Filed